HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $62

Benzinga · 2d ago
HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $48 to $62.